J. D. Parkes

7.0k total citations · 2 hit papers
104 papers, 4.6k citations indexed

About

J. D. Parkes is a scholar working on Neurology, Cognitive Neuroscience and Psychiatry and Mental health. According to data from OpenAlex, J. D. Parkes has authored 104 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Neurology, 27 papers in Cognitive Neuroscience and 15 papers in Psychiatry and Mental health. Recurrent topics in J. D. Parkes's work include Parkinson's Disease Mechanisms and Treatments (38 papers), Neurological disorders and treatments (29 papers) and Sleep and Wakefulness Research (24 papers). J. D. Parkes is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (38 papers), Neurological disorders and treatments (29 papers) and Sleep and Wakefulness Research (24 papers). J. D. Parkes collaborates with scholars based in United Kingdom, United States and Canada. J. D. Parkes's co-authors include C. D. Marsden, M. Dahlitz, C. D. Marsden, Niall Quinn, Jean Vignau, M Schachter, K J Zilkha, J. English, Joséphine Arendt and A G Debono and has published in prestigious journals such as Nature, The Lancet and Brain.

In The Last Decade

J. D. Parkes

102 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

"ON-OFF" EFFECTS IN PATIENTS WITH PARKINSON'S DISEASE ON CHRONIC LEVODOPA THERAPY

1976 523 citations C. D. Marsden, J. D. Parkes The Lancet profile →
SUCCESS AND PROBLEMS OF LONG-TERM LEVODOPA THERAPY IN PARKINSON'S DISEASE

1977 468 citations C. D. Marsden, J. D. Parkes The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J. D. Parkes United Kingdom	41	2.4k	1.2k	1.2k	806	657	104	4.6k
Santiago Perez‐Lloret Argentina	36	3.1k 1.3×	788 0.7×	1.0k 0.9×	416 0.5×	273 0.4×	131	4.9k
Meenakshisundaram Thiyagarajan United States	18	1.2k 0.5×	1.4k 1.2×	2.0k 1.7×	857 1.1×	990 1.5×	19	6.5k
E. Martignoni Italy	41	2.8k 1.2×	733 0.6×	1.3k 1.1×	118 0.1×	367 0.6×	172	6.1k
Tetsuo Shimizu Japan	35	471 0.2×	1.4k 1.2×	853 0.7×	1.3k 1.6×	1.2k 1.8×	175	4.4k
G Chazot France	33	600 0.2×	652 0.5×	570 0.5×	572 0.7×	1.5k 2.2×	119	4.0k
Agostino Baruzzi Italy	47	2.0k 0.8×	735 0.6×	1.2k 1.1×	239 0.3×	355 0.5×	200	7.2k
Harold L. Klawans United States	46	3.2k 1.3×	788 0.7×	2.7k 2.3×	146 0.2×	140 0.2×	210	6.9k
Nico J. Diederich Luxembourg	35	2.7k 1.1×	1.3k 1.1×	754 0.6×	209 0.3×	68 0.1×	88	4.0k
Piu Chan China	42	2.9k 1.2×	954 0.8×	1.1k 0.9×	115 0.1×	212 0.3×	128	5.0k
Holger Jahn Germany	37	494 0.2×	444 0.4×	881 0.7×	310 0.4×	303 0.5×	118	4.5k

Countries citing papers authored by J. D. Parkes

Since Specialization

Citations

This map shows the geographic impact of J. D. Parkes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. D. Parkes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. D. Parkes more than expected).

Fields of papers citing papers by J. D. Parkes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. D. Parkes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. D. Parkes. The network helps show where J. D. Parkes may publish in the future.

Co-authorship network of co-authors of J. D. Parkes

This figure shows the co-authorship network connecting the top 25 collaborators of J. D. Parkes. A scholar is included among the top collaborators of J. D. Parkes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. D. Parkes. J. D. Parkes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Schachter, M, M. P. Sheehy, J. D. Parkes, & C. D. Marsden. (2009). Lisuride in the treatment of Parkinsonism. Acta Neurologica Scandinavica. 62(6). 382–385. 2 indexed citations

2.

Parkes, J. D. & M Schachter. (2009). Mazindol in the treatment of narcolepsy. Acta Neurologica Scandinavica. 60(4). 250–254. 12 indexed citations

3.

Monk, C. R., A. Simmons, Gilbert Lemmens, et al.. (1999). Functional magnetic resonance imaging neuroactivation studies in normal subjects and subjects with the narcoleptic syndrome. Actions of modafinil. Journal of Sleep Research. 8(2). 85–93. 46 indexed citations

4.

Parkes, J. D., et al.. (1998). The clinical diagnosis of the narcoleptic syndrome. Journal of Sleep Research. 7(1). 41–52. 80 indexed citations

5.

Howard, Robert, Edward T. Bullmore, Michael Brammer, et al.. (1996). Functional echoplanar brain imaging correlates of amphetamine administration to normal subjects and subjects with the narcoleptic syndrome. Magnetic Resonance Imaging. 14(9). 1013–1016. 16 indexed citations

6.

Dahlitz, M., et al.. (1991). Delayed sleep phase syndrome response to melatonin. The Lancet. 337(8750). 1121–1124. 308 indexed citations

7.

Elwes, Robert, et al.. (1989). TREATMENT OF NARCOLEPSY WITH L-TYROSINE: DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL. The Lancet. 334(8671). 1067–1069. 10 indexed citations

8.

Critchley, Peter, et al.. (1988). Continuous subcutaneous lisuride infusions in Parkinson’s disease. PubMed. 27. 55–60. 9 indexed citations

9.

Lock, Christopher, A K So, K. I. Welsh, J. D. Parkes, & John Trowsdale. (1988). MHC class II sequences of an HLA-DR2 narcoleptic. Immunogenetics. 27(6). 449–455. 51 indexed citations

10.

Langdon, Nicola, et al.. (1986). Selegiline in Narcolepsy. SLEEP. 10(5). 491–495. 29 indexed citations

11.

Schachter, M, et al.. (1985). Amphetamine, mazindol, and fencamfamin in narcolepsy.. BMJ. 290(6476). 1167–1170. 41 indexed citations

12.

Thompson, Christopher, M Schachter, & J. D. Parkes. (1982). Drugs for cataplexy. Annals of Neurology. 12(1). 62–63. 3 indexed citations

13.

Lang, Anthony E., et al.. (1982). Early onset of the "on-off" phenomenon in children with symptomatic Parkinsonism.. Journal of Neurology Neurosurgery & Psychiatry. 45(9). 823–825. 27 indexed citations

14.

Parkes, J. D.. (1981). Adverse Effects of Antiparkinsonian Drugs. Drugs. 21(5). 341–353. 25 indexed citations

15.

Dobbs, Sylvia M., et al.. (1977). Oral digitalisation: choice of dose.. BMJ. 2(6080). 168–168. 3 indexed citations

16.

Debono, A G, C. D. Marsden, P. Asselman, & J. D. Parkes. (1976). BROMOCRIPTINE AND DOPAMINE RECEPTOR STIMULATION. British Journal of Clinical Pharmacology. 3(6). 977–982. 13 indexed citations

17.

Bergmann, S., et al.. (1974). THE ABSORPTION AND METABOLISM OF A STANDARD ORAL DOSE OF LEVODOPA IN PATIENTS WITH PARKINSONISM. British Journal of Clinical Pharmacology. 1(5). 417–424. 18 indexed citations

18.

Horrocks, P.M., et al.. (1973). Anticholinergic withdrawal and benzhexol treatment in Parkinson's disease. Journal of Neurology Neurosurgery & Psychiatry. 36(6). 936–941. 22 indexed citations

19.

Parkes, J. D., Iain M. Murray‐Lyon, & Roger Williams. (1970). NEUROPSYCHIATRIC AND ELECTROENCEPHALOGRAPHIC CHANGES AFTER TRANSPLANTATION OF THE LIVER<sup>1</sup>. QJM. 39(156). 515–27. 17 indexed citations

20.

Parkes, J. D. & J A McKinna. (1966). NEUROMUSCULAR BLOCKING ACTIVITY IN THE BLOOD OF PATIENTS WITH MYASTHENIA GRAVIS. The Lancet. 287(7434). 388–391. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact